We analyzed a cohort of 8558 adult AML patients who underwent HSCT from either a matched sibling or a matched unrelated donor demonstrating inferior LFS and patients with adverse cytogenetics and the added prognostic significance of FLT3-ITD to baseline cytogenetics in AML patients undergoing HSCT [31]. The gene discussed is FLT3; the disease is acute myeloid leukemia.